Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The design of a comparative treatment trial to evaluate the efficacy of therapeutics for progressive multifocal leukoencephalopathy (PML) is outlined. We propose a large simple randomized trial with patient survival as its primary endpoint, completed in a short period of time and involving a cohort with as few enrollment restrictions as possible. We use stratification as the counter-weight to the lack of exclusion criteria and suggest that proper stratification will attenuate differences inherent in a heterogeneous subject cohort. Estimation of power, sample size, and study duration, implementation of interim analyses, toxicity management, and validation of secondary clinical measures are also addressed.

Original languageEnglish (US)
Pages (from-to)369-374
Number of pages6
JournalJournal of NeuroVirology
Volume7
Issue number4
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Progressive Multifocal Leukoencephalopathy
Clinical Trials
Sample Size
Weights and Measures
Survival
Therapeutics

Keywords

  • Clinical protocol
  • HIV
  • Patient selection
  • Sample size

ASJC Scopus subject areas

  • Virology
  • Clinical Neurology

Cite this

Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy. / Yiannoutsos, Constantin; De Luca, A.

In: Journal of NeuroVirology, Vol. 7, No. 4, 2001, p. 369-374.

Research output: Contribution to journalArticle

@article{fd488420d4824ad3946604c2bf990c6e,
title = "Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy",
abstract = "The design of a comparative treatment trial to evaluate the efficacy of therapeutics for progressive multifocal leukoencephalopathy (PML) is outlined. We propose a large simple randomized trial with patient survival as its primary endpoint, completed in a short period of time and involving a cohort with as few enrollment restrictions as possible. We use stratification as the counter-weight to the lack of exclusion criteria and suggest that proper stratification will attenuate differences inherent in a heterogeneous subject cohort. Estimation of power, sample size, and study duration, implementation of interim analyses, toxicity management, and validation of secondary clinical measures are also addressed.",
keywords = "Clinical protocol, HIV, Patient selection, Sample size",
author = "Constantin Yiannoutsos and {De Luca}, A.",
year = "2001",
doi = "10.1080/13550280152537265",
language = "English (US)",
volume = "7",
pages = "369--374",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy

AU - Yiannoutsos, Constantin

AU - De Luca, A.

PY - 2001

Y1 - 2001

N2 - The design of a comparative treatment trial to evaluate the efficacy of therapeutics for progressive multifocal leukoencephalopathy (PML) is outlined. We propose a large simple randomized trial with patient survival as its primary endpoint, completed in a short period of time and involving a cohort with as few enrollment restrictions as possible. We use stratification as the counter-weight to the lack of exclusion criteria and suggest that proper stratification will attenuate differences inherent in a heterogeneous subject cohort. Estimation of power, sample size, and study duration, implementation of interim analyses, toxicity management, and validation of secondary clinical measures are also addressed.

AB - The design of a comparative treatment trial to evaluate the efficacy of therapeutics for progressive multifocal leukoencephalopathy (PML) is outlined. We propose a large simple randomized trial with patient survival as its primary endpoint, completed in a short period of time and involving a cohort with as few enrollment restrictions as possible. We use stratification as the counter-weight to the lack of exclusion criteria and suggest that proper stratification will attenuate differences inherent in a heterogeneous subject cohort. Estimation of power, sample size, and study duration, implementation of interim analyses, toxicity management, and validation of secondary clinical measures are also addressed.

KW - Clinical protocol

KW - HIV

KW - Patient selection

KW - Sample size

UR - http://www.scopus.com/inward/record.url?scp=0034833872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034833872&partnerID=8YFLogxK

U2 - 10.1080/13550280152537265

DO - 10.1080/13550280152537265

M3 - Article

C2 - 11517419

AN - SCOPUS:0034833872

VL - 7

SP - 369

EP - 374

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 4

ER -